Introduction
============

Chronic obstructive pulmonary disease (COPD) is a progressive disease associated with significant morbidity and mortality. The latest Global Initiative for Obstructive Lung Disease (GOLD) defines the disease as: "A common preventable and treatable disease, characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients" ([@B10]).

Several studies demonstrate that 86--98% of COPD patients have at least one comorbidity, with the average number per individual varying between from 1.2 to 4.0 ([@B21], [@B20]). Comorbidities often contribute to dyspnea, limitation of exercise capacity, deterioration of quality of life (QOL), increased healthcare utilization and cost, and increased exacerbation and mortality risk ([@B19]). COPD patients are more likely to die from a comorbid disease than COPD itself, as "only 40% of the deaths are definitely or probably related to COPD, with the remainder being mostly unrelated to COPD (50%) or unknown (9%)" ([@B14]). Based on this evidence, current guidelines for the management of COPD, besides treating chronic airflow limitation with traditional pharmacological therapy, adopt a more holistic approach by incorporating the assessment and appropriate treatment of comorbid diseases in order to ameliorate the health status and the prognosis of the patients (GOLD [@B10]).

Common comorbidities in patients with COPD include cardiovascular disease (CVD) (such as arterial hypertension, systemic venous thromboembolism (VTE), stroke, heart failure, coronary heart disease, arrhythmias and pulmonary hypertension), lung cancer and other cancers, psychiatric diseases (such as anxiety and depression disorders), metabolic conditions (such as malnutrition, obesity, diabetes mellitus, dyslipidemia), anemia, osteoporosis, musculoskeletal dysfunction, sleep disorders and gastroesophageal reflux ([@B19]). Some of these comorbidities (pulmonary artery disease and malnutrition) are directly caused by COPD (secondary to COPD), whereas others share common risk factors, such as lifestyle factors (e.g., smoking), environmental exposures (place of work, air pollution etc.), and genetic susceptibility, and are associated with similar pathophysiological mechanisms, like airway and systemic inflammation, lung hyperinflation and endothelial dysfunction and oxidative stress ([@B19]).

Pulmonary rehabilitation is an evidence-based intervention that is indicated for COPD patients who remain symptomatic -- despite optimal pharmacological therapy -- to reduce dyspnea, increase exercise capacity and improve QOL ([@B26]). Exercise training is the best available way of improving muscle function and exercise tolerance in patients with COPD ([@B29]). Moreover, regular physical activity is recommended and is beneficial for patients with CVD, musculoskeletal disease, obesity, diabetes mellitus and most other chronic medical conditions ([@B3]). However, a review on this topic concluded inconsistent data about pulmonary rehabilitation outcomes in COPD patients with comorbidities ([@B8]). For instance, patients with multiple comorbidities would present limited benefits from their participation in pulmonary rehabilitation ([@B5]), whereas most comorbidities were not related to rehabilitation outcomes ([@B6]). In most studies reported in the abovementioned review, outcomes were evaluated with functional exercise capacity as measured by six minute walking test (6MWT) and not with peak oxygen uptake (VO~2~peak) as measured during incremental exercise. Some studies proved worse outcomes in patients with cardiovascular, metabolic or psychological comorbid conditions, whereas others did not confirm this or reported opposite effects ([@B8]). Such knowledge would be of great practical value for practitioners working with COPD as it would allow them prescribing optimal pulmonary rehabilitation programs.

Therefore, the aim of our study was to further clarify pulmonary rehabilitation outcomes in stable COPD patients with coexisting comorbidities, in terms of specific diseases and total number. The principal end points were QOL, degree of dyspnea and aerobic capacity. We assessed exercise capacity using both 6MWT and VO~2~peak, in order to evaluate possible differences in results between the two methods.

Materials and Methods {#s1}
=====================

Thirty two patients with COPD (25 men and 7 women, age 66 ± 6 years, body mass index (BMI) 27.14 ± 4.88 kg/m^2^) ([Table 1](#T1){ref-type="table"}), sample of convenience, were selected for the present study from our outpatient clinics in the Division of Pulmonology, to the Department of Clinical Therapeutics of the National and Kapodistrian University of Athens School of Medicine, at Alexandra Hospital of Athens. COPD was diagnosed by history, physical examination, and standard pulmonary function tests according to GOLD criteria ([@B10]). Also, at baseline each patient underwent detailed general medical history -- including the number, the type and the medications of other coexisting diseases. Finally, each patient signed a written informed consent and the study protocol was approved by the Ethical Committee of our hospital. The study adheres to the CONSORT criteria ([Figure 1](#F1){ref-type="fig"}). All data are available in the [Supplementary Material](#SM1){ref-type="supplementary-material"}.

###### 

Baseline characteristics of participants.

  Parameters                             Total (*n* = 32)   Group 1 (*n* = 11)   Group 2 (*n* = 21)
  -------------------------------------- ------------------ -------------------- --------------------
  Patients (number (%), males/females)   25 (78%)/7 (22%)   10 (91%)/1 (9%)      15 (71%)/6 (29%)
  Age (years)                            66.03 ± 6.03       64.36 ± 5.45         66.91 ± 6.26
  BMI (kg/m^2^)                          27.14 ± 4.88       25.36 ± 4.73         28.07 ± 4.81
  FEV~1~ (L)                             1.297 ± 0.605      1.09 ± 0.53          1.40 ± 0.63
  FEV~1~ (% predicted)                   43.08 ± 15.07      35.78 ± 14.12        48.02 ± 15.16^∗^
  FEV~1~/FVC (%)                         51.67 ± 10.25      45.43 ± 6.93         54.94 ± 10.30^∗^
  RV/TLC (%)                             54.87 ± 19.68      68.20 ± 28.98        47.76 ± 5.73^∗^
  TLCO (% predicted)                     38.2 ± 22.8        21.7 ± 18.0          61.8 ± 20.0^∗^
  MRC                                    2.5 ± 0.9          2.5 ± 1.0            2.5 ± 0.9
  CAT                                    16.9 ± 9.3         15.6 ± 5.7           17.5 ± 10.8
  SGRQ                                   47.3 ± 19.0        41.1 ± 16.2          50.5 ± 20.0
  GOLD Severity (number, A/B/C/D)        1/9/14/8           0/2/4/5              1/7/10/3
  6MWT (m)                               280 ± 81           297 ± 95             271 ± 74
  Workload (W)                           58.4 ± 31.5        56.1 ± 29.6          59.5 ± 33.1
  VO~2~peak (mL min^-1^ kg^-1^)          13.2 ± 4.1         16.9 ± 5.0           11.9 ± 3.7^∗^
                                                                                 

BMI: Body Mass Index, FEV

1

: Forced Expiratory Volume in 1 s, FVC: Forced Vital Capacity, RV: Residual Volume, TLC: Total Lung Capacity, TLCO: Diffusing Capacity, MRC: modified Medical Research Council scale, CAT: COPD Assessment Test, SGRQ: St. George Respiratory Questionnaire, GOLD: Global Strategy for the diagnosis, management, and prevention of COPD, 6MWT: 6 min Walking Test, VO

2

peak: Peak Oxygen Uptake.

∗

p

\< 0.05

.

![CONSORT flow graph showing the enrollment, allocation, follow-up and analysis of participants.](fphys-10-00286-g001){#F1}

Eligible participants were 25 men and 7 women, with mean age 66 ± 6 years-old (range: 49--76) who met the following inclusion criteria: (1) COPD diagnosis of any stage (A, B, C, D), (2) stable condition, (3) optimal bronchodilation therapy, (4) optimal therapy of comorbidities, (5) reduced exercise capacity, and (6) completed successfully all parts of experimental intervention. Stable COPD was defined as no history of exacerbation in last 2 months prior to the study ([@B1]).

The patient population was divided in two groups, according to the presence or the absence of comorbidities. The comorbidities were both self-reported and confirmed in the medical records of the patients. Patients with none or only one comorbidity (*n* = 11, Group 1) were compared to those who had two or more comorbidities (*n* = 21, Group 2), in terms of dyspnea, QOL and exercise capacity, before and after a pulmonary rehabilitation program. The characteristics of each group were presented in [Table 1](#T1){ref-type="table"}. The experimental intervention was administered twice a week, for 13 weeks between 1 November 2012 and 31 December 2014 at the Division of Pulmonology, Department of Clinical Therapeutics of the National and Kapodistrian University of Athens School of Medicine, at Alexandra Hospital of Athens. Comorbidities were assessed using patient-report of a physician diagnosis.

At baseline, each patient underwent clinical examination, arterial blood gases analysis (GEM Premier 3500, United States), and Pulmonary Function Tests (PFTs) (Master screen Diffusion, Jaeger, Germany): spirometry (pre/post-bronchodilation), diffusing capacity and static lung volumes. Dyspnea was assessed by both the modified Medical Research Council (MRC) scale ([@B24]) and the COPD Assessment Test (CAT) ([@B12]). QOL was assessed by the St. George Respiratory Questionnaire (SGRQ) ([@B17]). BMI was calculated using patient's weight in kilograms (kg) divided by his or her height in meters squared.

Six minute walking test ([@B23]) and standard cardiopulmonary exercise test (Ergoline Variable 500, Viasys Health Care, Jaeger, Germany) were also carried out, while breathing room air. Expiratory oxygen and carbon dioxide fractions, work rate, airflow, cardiac frequency and oxygen saturation were continuously recorded. The results were obtained (1) at rest, (2) after 1 min of unloaded exercise, and (3) during incremental exercise. The incrementation rate was 25 W per minute. The pedaling frequency was constant at 60 revolutions per min. Each patient exercised against progressive workloads up to symptom-limited, maximum exercise capacity. All indications to stop the test were known by the personnel involved in the testing. The procedure was performed under the supervision of a physician trained in conducting exercise tests and in advanced cardiopulmonary resuscitation (CPR). Full CPR equipment was available in the laboratory.

After the initial assessment, each patient started an individualized rehabilitation program, at the Pulmonary Rehabilitation Department of Sotiria Hospital, twice a week, for a period of 13 weeks ([Table 2](#T2){ref-type="table"}). The program included (1) interval, endurance exercise training using cycle ergometer to 100% of WRmax of each patient, switching between exercise and rest, for 40 min, (2) continuous endurance exercise training using treadmill for 10--20 min, (3) lower and upper extremity strengthening exercise training-conditioning using mainly weight lifting for 5--15 sets, (4) breathing retraining (pursed lips breathing technique) and (5) respiratory muscle training. Education, diet and psychological support were provided by specialized personnel during the experimental period. Other important therapeutic modalities that were stressed during the program included smoking cessation, oxygen therapy, and use of bronchodilators and antibiotics. At the end of the 13 weeks period of training, the patients were reassessed using the same testing protocol.

###### 

Characteristics of pulmonary rehabilitation program.

  -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  General approach     The program was multimodal and evolutionary for each participant.
  Overall sessions     Twenty-five sessions for each participant.
  Content              Each session consisted by both physical therapy modalities for the respiratory system and exercise.
                       Exercise included both aerobic (treadmill, cycle ergometer and arm crank ergometer) and resistance training (3 set × 10--15 repetitions for 6--8 exercises of main muscle groups). Oxygen supply was provided continuously to maximize effort and exercise intensity maintaining hemoglobin saturation higher than 90%.
                       Physical therapy included relaxation techniques for dyspnea, pursed lips breathing technique, exercise of diaphragm/respiratory muscles and effective cough.
  Personnel            Participants were instructed by physical therapists under the guidance of physician and nurse.
  Frequency            Two sessions weekly (Monday and Thursday morning). The participants were encouraged and guided to perform an additional session by their own.
  Exercise intensity   Dyspnea was continuously monitored during each session using Borg scale and was considered to regulate exercise intensity.
                       
  -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The values of all functional parameters were expressed as mean and standard deviation (M ± SD). An independent *t*-test examined differences between the two experimental groups. A between-within subjects analysis of variance examined the main effect of time and the time × group interaction on QOL, dyspnea and exercise tolerance. The magnitude of the differences between experimental groups was examined using effect size eta square (η^2^) and was evaluated as following: small (0.010 \< η^2^≤ 0.059), moderate (0.059 \< η^2^≤ 0.138) and large (η^2^ \> 0.138) ([@B4]). The correlations among the pre-post changes in exercise tolerance, dyspnea or QOL, and the baseline COPD stage were examined using the Spearman correlation coefficient *rho*. The acceptable type I error was set at *p* \< 0.05.

Results
=======

The presence of comorbidities was very common (*n* = 28, 87.5% of patients) and included cardiovascular, diabetes mellitus, osteoporosis, psychological, and sleep disorders and cancers ([Table 3](#T3){ref-type="table"}). The two more frequently observed comorbidities were CVD and diabetes mellitus (*n* = 22, 68.8% and *n* = 17, 53.1%, respectively).

###### 

Prevalence of selected comorbidities in participants.

  Comorbidity                            Frequency (*n*)   Percentage (%)
  -------------------------------------- ----------------- ----------------
  Cardiovascular                         22                68.8
  Diabetes mellitus                      17                53.1
  Sleep apnoea and other lung diseases   5                 15.6
  Osteoporosis                           4                 12.5
  Lung cancer                            1                 3.1
  Other cancers                          5                 15.6
  Psychiatric                            3                 9.4
  Chronic kidney failure                 1                 3.1
  Gastrointestinal reflux                0                 0
                                                           

No statistically significant differences in performing the program were observed between the two groups. A large main effect of time was observed in MRC (*p* \< 0.001, η^2^= 0.665), CAT (*p* \< 0.001, η^2^= 0.621), SGRQ (*p* \< 0.001, η^2^= 0.457), which decreased, and in 6MWT (*p* \< 0.001, η^2^= 0.608), which increased across time ([Figure 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). No main effect of time was shown in body mass (*p* = 0.313, η^2^= 0.035), BMI (*p* = 0.251, η^2^= 0.045), FEV~1~ (*p* = 0.626, η^2^= 0.009) and VO~2~peak (*p* = 0.074, η^2^= 0.159). A large time ^∗^ group interaction was found in body mass (*p* = 0.012, η^2^= 0.198) with decrease in group 1 compared to group 2 and VO~2~peak (*p* = 0.025, η^2^= 0.238) with increase in group 1 compared to group 2. No time ^∗^ group interaction was observed in BMI (*p* = 0.249, η^2^= 0.046), MRC (*p* = 0.859, η^2^= 0.001), CAT (*p* = 0.279, η^2^= 0.039), SGRQ (*p* = 0.983, η^2^\< 0.001), 6MWT (*p* = 0.888, η^2^= 0.001) and FEV~1~ (*p* = 0.783, η^2^= 0.003). In summary, the indices of dyspnea (MRC and CAT), QOL (SGRQ) and aerobic capacity (6MWT) improved across time. The combined effect of group and time was shown only in body mass and VO~2~peak.

![The effect of pulmonary rehabilitation on dyspnea, quality of life (QOL) and aerobic capacity. Group 1 = patients with none or only one comorbidity, Group 2 = patients with two or more comorbidities, BMI = body mass index, FEV~1~ = forced expiratory volume in 1 s, MRC = modified Medical Research Council scale, CAT = COPD assessment test, SGRQ = St. George respiratory questionnaire, GOLD = global strategy for the diagnosis, management, and prevention of COPD, 6MWT = 6 min walking test, VO~2~peak = peak oxygen uptake. ^∗^group × time interaction at *p* \< 0.05, \#main effect of time at *p* \< 0.05.](fphys-10-00286-g002){#F2}

![Inter-individual variability in changes of dyspnea, QOL and aerobic capacity following pulmonary rehabilitation. BMI = body mass index, FEV~1~ = forced expiratory volume in 1 s, MRC = modified Medical Research Council scale, CAT = COPD assessment test, SGRQ = St. George respiratory questionnaire, GOLD = global strategy for the diagnosis, management, and prevention of COPD, 6MWT = 6min walking test, VO~2~peak = peak oxygen uptake.](fphys-10-00286-g003){#F3}

The severity of the disease was not significantly associated with any of the observed changes after the rehabilitation program (rho ≤ 0.23, *p* ≥ 0.205). Only the reduction of dyspnea tended to be less -- but not statistically significant -- in severe and very severe COPD patients when compared to mild and moderate COPD patients (DMRC: 33% vs. 50%).

VO~2~peak showed a significant percentage increase of 25.7% in the subgroup of patients with none or one comorbidity (Group 1) compared to the subgroup of patients with two or more comorbidities (Group 2). However, the total number or/and specific comorbidities (CVD and diabetes mellitus) were not related to the general outcomes of pulmonary rehabilitation program, according to the correlation analysis. No harm was observed in participants.

Discussion
==========

Our prospective study demonstrated that all COPD patients improved, after a 13 week pulmonary rehabilitation program, in terms of dyspnea (MRC and CAT), QOL (SGRQ) and exercise tolerance in 6MWT, independently of the presence, the number or the nature of their comorbidities. We did not observe significant responses in FEV~1~ or VO~2~peak. To the best of our knowledge, this is the first study that evaluates the results of a rehabilitation program by both 6MWT and CPET.

It is well documented that pulmonary rehabilitation reduces dyspnea, improves QOL and increases exercise capacity in COPD patients ([@B26]), especially in those who remain symptomatic despite maximal pharmacological therapy. Although COPD is characterized by multi -- morbidity, which leads to worse disease symptoms, increased health care utilization and significant mortality, available data about the effect of comorbidities on pulmonary rehabilitation outcomes in COPD still conflicting ([@B5], [@B6]; [@B8]).

Most previous studies, that reported worse response after rehabilitation, in COPD patients with co-existing cardiovascular or metabolic diseases, were retrospective ([@B5]; [@B27]; [@B2]). In some studies, health status and/or 6MWT were negatively influenced by the presence of cardiac or metabolic diseases ([@B5]; [@B27]; [@B2]). On the contrary, another retrospective study, reported better response in 6MWT in COPD patients with metabolic diseases ([@B28]). BMI \> 25 kg m^-2^ was an independent predictor of improvement in 6MWT, but not in SGRQ, in one study ([@B27]), whereas other studies did not observe any difference between obese and non-obese patients ([@B22]; [@B11]). Psychological symptoms led to reduced improvement in dyspnea ([@B2]) and increased risk of drop-out of the program ([@B9]).

Our study was prospective and our data were in partial accordance with previous studies. All COPD patients, independently of the number or the nature of comorbidities, achieved less dyspnea and better QOL after the rehabilitation program. The level of dyspnea was higher and tended to ameliorate less -- but not statistically significant -- in severe and very severe COPD patients, compared to moderate and mild patients. Probably more severe patients have more dyspnea and a significant degree remains even after the intervention. Cardiovascular or metabolic comorbidities were not associated with the outcomes of the rehabilitation program.

The objective performance of participants was measured by both 6MWT and CPET. All patients improved in 6MWT, but not in workload or VO~2~peak. In previous studies the most commonly assessed test was the 6MWT. It is reliable, simple, and of low cost. Furthermore, 6MWT resembles daily activities, as patients use to walk and not to cycle. However, changes in the 6MWT are not significantly correlated to changes in other indices of exercise performance ([@B18]), as it only measures a narrow range of the physical performance spectrum. Also, the 6MWT appears to be less sensitive to intervention than the CPET ([@B7]). Group 1 achieved significantly better VO~2~peak compared to Group 2, after the rehabilitation program. This was in accordance with a previous study which showed that the improvement in exercise capacity was significantly greater in patients without significant comorbidities ([@B5]).Probably patients with better baseline condition have greater possibility for improvement.

The amelioration of symptoms and exercise capacity, as expressed by 6MWT, in the whole population -- independently of coexisting comorbidities -- can be explained by the fact that physical activity and regular exercise are beneficial not only for patients with COPD, but also for patients with CVD, musculoskeletal disease, obesity, diabetes mellitus and most other chronic medical conditions ([@B8]). Moreover, in patients with heart failure or diabetes mellitus type 2, prescribed exercise, involving aerobic and resistance training modalities, is also evidence-based treatment ([@B15]). Thus, pulmonary rehabilitation is beneficial for individuals with COPD and comorbidities, as it has positive effects on both.

The major limitation of our study is the small number of the patients. Besides, the severity of their comorbidities is not quantified and we considered only the number of presented comorbidities (i.e., none or one versus two to nine). Also, a major point of discussion is whether the results suggest real pathophysiologic differences in the response to pulmonary rehabilitation or are due to a greater deconditioning in chronic illness patients. On the other hand, strength of the study was its novelty as limited information existed so far about the role of the number of comorbidities on the effectiveness of a rehabilitation program for COPD ([@B16]). Considering the high prevalence of COPD ([@B25]) and the key role of comorbidities ([@B13]), the findings of the present study were of great practical importance for practitioners working with COPD.

Conclusion
==========

We conclude that all COPD patients benefit from a pulmonary rehabilitation program, independently of comorbidities. More severe patients and patients with ≥2 comorbidities have inferior outcomes when compared to moderate or to patients with 0--1 comorbidity. More studies are required to evaluate the effects of this intervention in the natural history of COPD and comorbidities.
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Pre-intervention values for each participant.
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Click here for additional data file.
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Post-intervention values for each participant.
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6MWT

:   six minute walking test

ATS

:   American Thoracic Society

BMI

:   body mass index

CAT

:   COPD assessment test

COPD

:   chronic obstructive pulmonary disease

CPR

:   cardiopulmonary resuscitation

CVD

:   cardiovascular disease

GOLD

:   global initiative for obstructive lung disease

MRC

:   medical research council

QOL

:   quality of life

SGRQ

:   St. George respiratory questionnaire

VO~2~peak

:   Peak oxygen uptake

VTE

:   systemic venous thromboembolism
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